PATENT 10/8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants of: Voorberg, et al.

Group Art Unit: 1645

Serial No.: 09/674,752

Examiner: Unassigned

Filed: December 29, 2000

Docket: 294-86 PCT/US

For: METHOD FOR DIAGNOSIS AND TREATMENT OF HEMOPHILIA A PATIENTS WITH AN INHIBITOR

Dated: October 25, 2002

Commissioner for Patents
Washington, D.C. 20231

I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202

20231 on October 25, 2002

Dated: 10/25/02 Julie L. Watts

AMENDMENT

Sir:

This amendment is submitted to response to the Notification of Defective Response dated September 25, 2002. Applicants respectfully requests entry of the following amendments.

IN THE SPECIFICATION

Please amend the third paragraph beginning on page 6, line 17, as follows:

Figure 3 shows the nucleotide sequence of clone EL14 (SEQ. ID. NO: 19) and clone IT2 (SEQ. ID. NO: 21). The nucleotide sequence of both clones is aligned with the nucleotide sequence of the germline sequences DP-10 (SEQ. ID. NO: 20) (for EL14) and DP-14 (SEQ. ID. NO: 22) (for IT2). The different regions of the variable part of the heavy chain are indicated in the following order: framework 1, CDR1, framework 2, CDR2, framework 3, CDR3 and framework 4. Homology of clones EL14 and IT2 with the germline sequences DP-10 and DP-14 is indicated by horizontal bars (-). Differences are indicated by the nucleotides that occur in the germline sequences DP-10 and DP-14. Note that both CDR3 and framework 4 are not derived from the germline sequences DP-10 and DP-14. Consequently, no homology is given for this part of the nucleotide sequence.